Health ConditionsEye floaters are shapes or dots that may be noticed when looking at a clear sky, a blank piece of paper, or a white wall. The medical name for these shapes or dots is myodesopsia. They are small visual disturbances that appear to drift across the line of sight, especially noticeable against bright or plain backgrounds like a blue sky or white wall.
Floaters can take many different shapes. Some patients describe them as small dots, while others see squiggly lines, rings, or cobweb-like formations. They tend to move when one tries to look directly at them, drifting in the direction the eye moves and then settling slowly when the eye stops.
Floaters typically appear as moving shadows, threads, or rings that drift with eye movement. In severe cases, they degrade contrast sensitivity and noticeably impair vision and quality of life.
The vitreous humor is a transparent, colorless, gel-like substance that fills the space between the lens and the retina within the eye. It is composed of mostly water, along with a small percentage of collagen, glycosaminoglycans (sugars), electrolytes (salts), and proteins. The human eye is divided into two segments, the anterior (front) segment and the posterior (back) segment. The vitreous humor is located in the posterior segment and fills the vitreous chamber, which takes up about 80% of the eye.
The vitreous gel is about 99 percent water and contains a network of collagen fibers that help it maintain its shape. The vitreous fills the space between the lens at the front of the eye and the retina at the back, and light must pass through it before reaching the retina. When tiny clumps, fibers, or debris form within the vitreous, they cast shadows on the retina, and those shadows are what are perceived as floaters.
The vitreous gel is composed of collagen fibers and a highly hydrated extracellular matrix, including hyaluronic acid (HA) and chondroitin sulfate proteoglycans (CS), that maintains biodegradable and biocompatible activities. Most of the water in the vitreous is bound in the widely-spaced supporting framework of collagen fibers and HA. Initially, HA and CS keep the vitreous collagen fibrils apart.
Vitreous floaters are microscopic collagen fibers within the vitreous that tend to clump and cast shadows on the retina, appearing as floaters to the patient. The most common cause of vitreous floaters in ophthalmology is posterior vitreous detachment (PVD), a separation of the posterior hyaloid face from the retina.
With aging, the vitreous humor can contract and separate from the retina. The age at which this change occurs varies but most often is between 50 and 75 years. During this separation, the vitreous can intermittently tug on the retina. The mechanical traction stimulates the retina, which sends a signal that is perceived by the brain and interpreted as light. Complete separation of the vitreous leads to an increase in floaters, which may last for years.
With aging, pathological processes and oxidative stress occur, leading to HA depolymerization, water loss, vitreous liquefaction, and disorganization of the collagen fibrils. This phenomenon results in the formation of larger fibrils, which float in lacunas of liquefied vitreous. Moreover, the disordered collagen fibrils and HA mix and generate vitreous opacities. These opacities in the vitreous are projected onto the retina and are interpreted by the brain as moving objects.
Oxidative stress (secondary to increased intravitreal free radicals), accumulation of nonenzymatic glycation end products, and decreased vitreous antioxidant capacity underpin vitreous degeneration, typified by vitreous collagen aggregation and glycation as well as hyaluronan depolymerization.
Normal aging of the eye is accompanied by progressive degeneration characterized by vitreous liquefaction (synchysis) and weakening of the vitreoretinal adhesion. This degeneration, corresponding with a simultaneous decrease in gel volume, a lateral aggregation of the collagen fibrils (syneresis), and a gradual destruction of the collagen-hyaluronate network, may result in posterior vitreous detachment (PVD).
Aging is associated with degeneration of vitreous structure as well as a reduction in its antioxidant capacity. A growing body of evidence suggests these age-related changes may be the precursor of numerous oxidative stress-induced vitreo-retinopathies, including vision-degrading myodesopsia, the clinically significant entoptic phenomena that can result from advanced vitreous degeneration. Adequate intravitreal antioxidant levels may be protective against vitreous degeneration, possibly preventing and even improving vision-degrading myodesopsia as well as mitigating various other vitreo-retinopathies.
An in vitro study published in Investigative Ophthalmology & Visual Science (IOVS) illuminated the role of hyaluronic acid in particular: depletion of hyaluronic acid from the vitreous majorly increased vitreous straylight (mean increase 34.4 deg²/sr; P = 0.01), whereas primarily digesting the vitreous gel with collagenase or trypsin did not significantly affect straylight. This finding points to hyaluronic acid as a key structural protector of vitreous clarity.
Age is one of the most important factors in the development of myodesopsia. As people age, their eyes can undergo significant changes. The vitreous, which is the gel that occupies the inside of the eye, changes over time, which can lead to the formation of opacities. This process is normal but becomes more evident from the age of 50.
Individuals with high myopia (greater than –6 dioptres) have a vitreous that ages prematurely and an elongated eye whose peripheral retina is more fragile. They develop floaters earlier and are at greater risk of retinal tears and retinal detachment. Highly myopic patients are at elevated risk at younger ages because axial elongation accelerates vitreous changes.
In diabetic retinopathy, new, weak blood vessels can leak into the vitreous. If the amount of bleeding is small, only a few dark spots, called floaters, may be seen. In more severe cases, blood can fill the vitreous cavity and completely block vision. Most floaters result from age-related or myopic changes in the vitreous body, with PVD being the most common cause. Other factors include vitreous syneresis, asteroid hyalosis, hemorrhage, diabetes, and trauma.
Posterior uveitis (inflammation of the posterior segment of the eye) can cause floaters, often associated with a sensation of haziness or reduced vision. These inflammation-related floaters may be bilateral and accompanied by other systemic signs. The origin may be infectious (toxoplasmosis, herpes) or immune-mediated (sarcoidosis, Behçet's disease, etc.).
Additional risk factors include eye trauma, diabetes (due to diabetic retinopathy risk), previous intraocular surgery, and a history of uveitis. Persons who have been subjected to cataract surgery may encounter an increase in the occurrence of floaters. During the procedure, the vitreous may be disrupted, which in turn may affect visual perception post-operatively.
In patients without PVD, floaters may result from conditions such as asteroid hyalosis, uveitis, or, more commonly, myopic vitreopathy. Although the precise etiological mechanisms behind myodesopsia in many instances remain unknown—and the condition is often deemed "idiopathic"—there are strong reasons to suspect that such cases may be indicative of a susceptibility to collagen degradation in response to inflammatory triggers.
The following sections distinguish between traditional use (historical or ethnobotanical application without formal clinical evidence) and scientific evidence (data from cell, animal, or human studies, with explicit attention to study quality and limitations). It should be noted that the overall evidence base for any natural intervention specifically targeting floaters remains limited; the FLIES trial described below represents the most rigorous direct evidence to date.
Traditional use: Vitamin C has long been recognized in many herbal and folk medical traditions as a wound-healing and anti-inflammatory nutrient, and is widely included in multi-ingredient "eye health" formulas in Western naturopathic practice.
Scientific evidence: Vitamin C guards against intraocular oxidative stress by consuming oxygen released at the vitreoretinal interface in an ascorbate-dependent fashion. The vitreous humor is known to contain high concentrations of ascorbic acid, which functions as a primary antioxidant within the ocular environment. Vitamin C helps counter intraocular oxidative stress by consuming reactive oxygen species and free radicals in an ascorbate-dependent manner.
In the FLIES randomized controlled trial (discussed in detail below), vitamin C was one of the key active ingredients. The findings of this study indicate improvements in vision-related quality of life and visual function of patients suffering from vitreous floaters after supplementation with a formulation of antioxidative and antiglycation micronutrients. These improvements were confirmed by the decrease in vitreous opacity areas in the active group. This is moderate-quality evidence, limited by small sample size.
Traditional use: Zinc has been used in Ayurvedic and other traditional systems as a mineral tonic for ocular conditions, often in combination with other herbs. In Western herbal medicine it is frequently included in eye-health nutritional formulas.
Scientific evidence: Zinc acts as a stimulus for the synthesis of metallothionein, a metal-binding protein which protects tissues from glycoxidation (a mechanism that leads to vitreous degeneration). Zinc has also been shown to possess antioxidative and antiglycation properties, and zinc supplementation could inhibit formation of advanced glycation end-products and advanced glycation end product–induced oxidative stress. In the FLIES trial, zinc was included at 5 mg/day as part of the active formulation. Evidence strength: preliminary (single trial, small sample).
Traditional use: L-Lysine is an essential amino acid with no classical traditional herbal use specific to the eye. Its inclusion in modern nutritional protocols for vitreous health is based on biochemical rationale rather than historical tradition.
Scientific evidence: L-Lysine prevents collagen glycation and also acts as a chemical chaperone. L-Lysine, an essential free amino acid, helps prevent collagen glycation and serves as a chemical chaperone—meaning it assists in maintaining the correct folding and structural integrity of proteins, including vitreous collagen. In the FLIES trial, L-lysine was administered at 125 mg/day. Evidence is preliminary and derives from a single clinical trial.
Traditional use: Grape seed and grape leaf preparations have been used in European folk medicine and are described in various herbalist traditions for circulatory and vascular support. Proanthocyanidins from grape seeds have historically been used in France for capillary fragility conditions (as oligomeric proanthocyanidins, OPCs), including those affecting the eye.
Scientific evidence: Proanthocyanidin in V. vinifera exerts an inhibitory effect on protein glycation. Proanthocyanidins have been shown to inhibit protein glycation. Hesperidin regulates oxidative stress and reduces the level of inflammatory cytokines by inhibiting the formation of advanced glycation end products, and therefore it could help prevent collagen aggregation. In the FLIES trial, 26.3 mg of Vitis vinifera extract per day was used. Evidence is preliminary.
Traditional use: Citrus aurantium (bitter orange) and its flavonoid hesperidin have been used in Traditional Chinese Medicine and in European folk medicine for digestive complaints, blood vessel support, and anti-inflammatory purposes.
Scientific evidence: Hesperidin prevents oxidative stress by inhibiting the formation and accumulation of cross-linking advanced glycation end products in collagens and tissues. In the FLIES trial, 100 mg/day of Citrus aurantium was employed as the hesperidin source. The evidence remains preliminary, derived from a single small trial.
The Floater Intervention Study (FLIES) is the most robust clinical evidence currently available for a nutritional approach to floaters. FLIES is a registered (ISRCTN15605916), parallel group, single-center, double-blind, randomized, placebo-controlled clinical trial designed to investigate the impact of supplementation with an active formulation of antioxidative and antiglycation micronutrients on the visual discomfort experienced by floater sufferers.
In this clinical trial, 61 patients with symptomatic vitreous floaters were randomized to consume daily the active supplement consisting of 125 mg L-lysine, 40 mg vitamin C, 26.3 mg Vitis vinifera extract, 5 mg zinc, and 100 mg Citrus aurantium or placebo for 6 months. Change in visual discomfort from floaters, assessed with the Floater Disturbance Questionnaire, was the primary outcome measure. Secondary outcome measures included best-corrected visual acuity, letter contrast sensitivity, photopic functional contrast sensitivity with positive and negative contrast polarity, and quantitative vitreous opacity areas.
Results showed that after supplementation, the active group reported a significant decrease in their visual discomfort from floaters (P < 0.001), whereas the placebo group had no significant change in their visual discomfort (P = 0.416). A large percentage of patients (77%) on the active supplement demonstrated a reduction in vitreous floaters, and associated improvements in vision-related quality of life were seen in 67% of patients.
The observed benefit in the active group confirms the hypothesis that dietary intake of a formulation of antioxidative and antiglycation micronutrients could avail relevant micronutrients capable of mitigating the mechanisms underlying vitreous degeneration, thereby decreasing the visual discomfort associated with vitreous floaters.
Limitations: The inclusion criteria for this study specified primary floaters (age-related or myopia-related onset) in at least one eye, with participants 18 years and older, and excluded those with cataract surgery, neural, developmental, or retinal disease (such as retinal breaks or detachments, age-related macular degeneration, diabetic retinopathy, and branch retinal vein occlusion). The study was a single-center trial with a relatively small sample size (61 participants), and the active formulation was a multi-ingredient combination, precluding determination of which individual components were responsible for any benefit. Replication in larger, multi-center trials is required.
Traditional use: Curcumin, derived from turmeric (Curcuma longa), has a long history in Ayurvedic and Traditional Chinese Medicine for anti-inflammatory conditions. Its application to eye floaters or vitreous health is a modern, science-driven use, not a historical traditional one.
Scientific evidence: Curcumin has demonstrated several biological effects in vitro, in animal models, and in clinical studies of ocular diseases. For instance, it promotes corneal wound healing and epithelial barrier protection, has shown efficacy in treating dry eye (anti-inflammatory), and offers benefits in the prevention of glaucoma (neuroprotective), age-related macular degeneration (anti-apoptotic), and diabetic retinopathy (antioxidant and anti-angiogenic).
A 2025 pilot study (Malandrini et al., University of Siena, published in Vision) evaluated a multi-ingredient supplement in a specific clinical context: the study evaluated the short-term effects of a dietary supplement containing curcumin, bromelain, glucosamine, chondroitin sulphate, sodium hyaluronate, type II collagen, and vitamin C on symptomatic vitreous floaters (SVFs) following Nd:YAG laser capsulotomy. Forty eyes with SVFs on the first postoperative day were randomized into a control group (standard topical therapy, n = 20) and a treatment group (oral supplement plus standard therapy, n = 20). On average, in the group taking the dietary supplement, contrast sensitivity was about two triplets higher, questionnaire scores (floaters perception, interference with daily activities, and foreign body sensation) were each about one point lower, ultrasound vitreous peaks were one point lower, and grey intensity was around 40% lower. No supplement-related adverse events were reported. This evidence is preliminary (small pilot study, specific post-surgical population, short-term follow-up) and the multi-ingredient design precludes attribution to curcumin alone.
Traditional use: Bromelain is a proteolytic enzyme complex derived from the stem of pineapple (Ananas comosus). It has been used in folk medicine across Latin America and in integrative medicine for anti-inflammatory and digestive purposes. Its use for eye conditions is modern.
Scientific evidence: Bromelain is a fibrinolytic enzyme originating from the stem of pineapples (Ananas comosus L. Merr.), exhibiting anti-inflammatory and anti-edematous properties, along with a recognized proteolytic function on primary and hematic vitreous floaters. The IOVS in vitro study referenced earlier also tested bromelain's effects on vitreous straylight: fifty-seven porcine vitreous bodies were digested using hyaluronidase, collagenase, trypsin, and bromelain, as well as using combinations of these enzymes, to study the effects on forward light scattering. Bromelain's evidence for floater reduction in humans derives largely from small, uncontrolled studies or from its inclusion in multi-ingredient formulas (such as the Malandrini 2025 pilot and a 2022 Taiwanese study on mixed fruit enzymes); robust, isolated human trials are lacking.
Traditional use: These compounds, widely used in the context of joint health, do not have a traditional history of use specifically for vitreous or ocular conditions. Their inclusion in vitreous health formulas is based on the biochemical rationale that these are structural components of the vitreous gel itself.
Scientific evidence: Type II collagen and mucopolysaccharides, glucosamine, chondroitin sulphate, and sodium hyaluronate constitute the fibrillary structure of the vitreous, are often associated with vitamin C, a known cofactor in collagen synthesis, and are thought to remodel and repair the fibrillary vitreous structure disrupted by the natural ageing process (synchysis and syneresis). These compounds were included in the Malandrini 2025 pilot study supplement, but human evidence for their benefit in floaters in isolation is absent. Evidence is in vitro/mechanistic only.
Traditional use: Lutein and zeaxanthin are carotenoids found abundantly in leafy greens and egg yolks. While no classical herbal tradition specifically recommended these compounds for vitreous health, dietary traditions rich in green vegetables are widespread globally and have long been associated with general eye health.
Scientific evidence: These carotenoids are primarily studied in the context of macular health and age-related macular degeneration (AMD), not floaters specifically. Lutein and zeaxanthin are hydroxylated carotenoids that selectively accumulate in the macula, forming the macular pigment optical density (MPOD). These xanthophylls function through selective blue light filtration (400–500 nm wavelength) and direct antioxidant activity within photoreceptor outer segments. Studies have mostly focused on how lutein supports macular health, not floater reduction. It may protect parts of the eye from oxidative damage that can contribute to floaters, but more research is needed. The evidence for direct benefit to the vitreous or to floaters specifically is absent; their relevance here is indirect, through general antioxidant protection of ocular tissues.
Traditional use: Fish and fish oil consumption for eye and overall health has historical roots in coastal and Nordic dietary traditions.
Scientific evidence: Omega-3 fatty acids have well-documented benefits for retinal health and dry eye, but their direct relationship to vitreous floaters has not been established in clinical trials. Omega-3 fatty acids modulate inflammatory signaling pathways, potentially reducing inappropriate inflammatory responses within the eye. Omega-3s are well-supported for dry eye and meibomian gland dysfunction, but not specifically for floaters. The evidence for omega-3 supplementation improving floaters is currently absent from the peer-reviewed literature.
Traditional use: No classical traditional use exists for oral hyaluronic acid in the treatment of eye floaters.
Scientific evidence: As a structural component of the vitreous, hyaluronic acid depolymerization is directly implicated in vitreous degeneration and floater formation. The in vitro IOVS study demonstrated that its depletion significantly increases vitreous straylight. Hyaluronic acid attracts water and may help with eye hydration and comfort, although it is unlikely to affect floaters directly when taken orally. Evidence for oral supplementation reducing floaters is lacking.
Floaters and AMD both become more likely as people get older and share risk factors such as oxidative stress and poor diet. There is no proven natural remedy or supplement that removes floaters, but some nutrients may support overall eye health and collagen integrity. A diet rich in antioxidants, omega-3s, lutein, and zeaxanthin can help support the retina and may reduce the risk of age-related eye conditions.
The question of whether supplements and lifestyle changes can slow the ageing process in the eye, delaying the onset of these age-related floaters, remains an open one. The main reason floaters occur is age. With age, the vitreous—a clear, gel-like substance inside the eye—starts to thicken and shrink. Vitreous consists mostly of water, collagens, and an acid called hyaluronan. Over time, the vitreous degenerates slightly and little clumps of collagen begin to form.
As part of ageing, the vitreous humour can become dehydrated. This decrease in water not only alters the consistency of the gel, but also allows condensation to form which, when projected onto the retina, creates the perception of floaters. Maintaining adequate daily hydration is therefore discussed in the literature as a general supportive measure for vitreous integrity, though no formal clinical trials have tested the effect of increased water intake specifically on floater incidence or severity.
The glycation of vitreous collagen is a central biochemical mechanism in floater formation, making dietary glycemic load a theoretically relevant factor. Accumulation of nonenzymatic glycation end products and decreased vitreous antioxidant capacity underpin vitreous degeneration. In diabetes specifically, over time, too much sugar in the blood causes damage to the tiny blood vessels that nourish the retina, cutting off its blood supply, which can in turn produce floaters through vitreous hemorrhage. No specific dietary glycemic index trials have been conducted with floaters as the primary outcome.
Smoking increases the risk of many diabetic complications, including diabetic retinopathy, a secondary cause of floaters. More broadly, smoking-induced oxidative stress is recognized as a general accelerant of ocular tissue aging. This is indirect evidence; no trials have specifically measured the impact of smoking cessation on floater incidence.
High-energy light sources are recognized as contributors to oxidative stress within the vitreous. Oxidative changes in collagen fibers play a role in the development of vitreous opacity. High-energy light sources and oxygen pressure from the retina generate reactive oxygen species, known as free radicals, which trigger this process. Protective use of UV-filtering sunglasses is discussed in general eye health literature in this context, though specific floater prevention trials do not exist.
Exercise regularly to improve blood circulation, delivering essential nutrients and oxygen to the eyes is a recommendation appearing in eye health literature in the context of general ocular well-being, including vitreous health. No specific clinical trials have examined exercise interventions for floater prevention or reduction.
It is doubtful that lifestyle changes will have a direct impact on existing floaters, but they may be great health advice generally and might delay the ageing processes in the eye by which floaters arrive. For the majority of patients, floaters are mild, non-progressive, and do not significantly impact vision. In such cases, the standard approach is observation and reassurance. Many individuals adapt to their floaters over time as the brain learns to ignore the shadows.
Bromelain, a fibrinolytic protease from pineapple, has been tested in multiple double-blind RCTs for vitreous floater reduction. Two Taiwanese RCTs (n=280 and n=224) found high-dose mixed-fruit-enzyme supplementation including 190 mg bromelain significantly reduced vitreous opacities over 3 months. A 2025 pilot RCT also included bromelain in a multi-ingredient floater supplement with significant clinical results.
Chondroitin sulphate was included in the 2025 pilot RCT combination supplement (n=40 eyes) for post-Nd:YAG capsulotomy floaters, where the treatment arm showed significant improvements in floater perception and contrast sensitivity. Chondroitin sulphate is a native vitreous glycosaminoglycan proposed to support structural vitreous matrix repair.
Type II collagen, the principal structural protein of the vitreous humor, was included in the 2025 pilot RCT combination supplement (n=40 eyes) for post-Nd:YAG floaters, where the treatment group showed significant improvements in floater perception and contrast sensitivity. It is proposed to provide substrate for vitreous fibrillary matrix repair alongside vitamin C and glycosaminoglycans.
Curcumin was tested in a 2025 pilot RCT (n=40 eyes, University of Siena) in a multi-ingredient oral supplement for symptomatic vitreous floaters post-Nd:YAG capsulotomy, with significant improvements in floater perception and contrast sensitivity versus standard therapy. Its anti-inflammatory (NF-ÎşB inhibition) and antioxidant properties are the proposed mechanism.
Glucosamine was one of seven active ingredients in the 2025 pilot RCT combination supplement (n=40 eyes) for post-Nd:YAG capsulotomy floaters, where the treatment group showed significant improvements in floater perception and contrast sensitivity. As a building block of vitreous glycosaminoglycans, it is proposed to support vitreous matrix remodeling.
Hyaluronic acid, the primary glycosaminoglycan of the vitreous humor, was included in the 2025 pilot RCT combination supplement (n=40 eyes) for post-Nd:YAG floaters that showed significant improvements in floater perception and contrast sensitivity. Its depolymerization with ageing directly underlies floater formation, and HA is used as a vitreous substitute in ophthalmic surgery.
L-lysine (125 mg/day) was a core ingredient in the FLIES double-blind, placebo-controlled RCT (n=61, 6 months) that produced a significant reduction in floater-related visual discomfort and vitreous opacity areas versus placebo. Its mechanism is inhibition of non-enzymatic glycation of vitreous collagen, a key driver of vitreous degeneration.
Papain, a cysteine protease from papaya, was co-administered at 95 mg/day with bromelain and ficin in two Taiwanese double-blind RCTs (n=280 and n=224) that found high-dose mixed-fruit-enzyme supplementation significantly reduced vitreous opacities over 3 months. Its proposed action is proteolytic dissolution of disorganized vitreous collagen fibrils.
Vitamin C (40 mg/day) was part of the FLIES RCT combination (n=61, 6 months) that significantly reduced floater visual discomfort and vitreous opacity areas versus placebo, and it also appeared in the 2025 pilot RCT formulation for post-laser floaters. It serves as a vitreous antioxidant and collagen synthesis cofactor.
Zinc (5 mg/day) was included in the FLIES RCT combination (n=61, 6 months) that significantly reduced floater visual discomfort and vitreous opacity areas versus placebo. It contributes antioxidant properties via superoxide dismutase and antiglycation activity relevant to vitreous collagen integrity.
Go back